

**GENERAL ASSEMBLY OF NORTH CAROLINA**  
**SESSION 2007**

**H**

**D**

**HOUSE DRH70465-LN-216B (3/13)**

Short Title: Funds/Institute for NanoMedicine.

(Public)

---

Sponsors: Representative Womble.

---

Referred to:

---

A BILL TO BE ENTITLED

1  
2 AN ACT TO APPROPRIATE FUNDS TO THE DEPARTMENT OF COMMERCE  
3 FOR ACTIVITIES AND OPERATIONS OF THE NORTH CAROLINA  
4 INSTITUTE OF NANOMEDICINE.

5 Whereas, the North Carolina Institute of NanoMedicine (NCNanoMed) will  
6 create economic development and expansion of nanomedicine- and regenerative  
7 medicine-based biotech companies located in or that would relocate to North Carolina  
8 leading to a projected 6,000 new jobs over the next 5-10 years with an average annual  
9 salary of \$87,000; and

10 Whereas, NCNanoMed will establish North Carolina as the gateway for  
11 nanomedicine in the United States for United States-based companies and for  
12 international-based therapeutics companies needing access to regulatory (FDA)  
13 approval for entry of their drugs or devices in the United States market; Now, therefore,  
14 The General Assembly of North Carolina enacts:

15 **SECTION 1.** There is appropriated from the General Fund to the  
16 Department of Commerce the sum of fifteen million dollars (\$15,000,000) for the  
17 2007-2008 fiscal year. These funds shall be used in the development and furtherance of  
18 the nanomedicine industry, which includes the monitoring, repair and regeneration,  
19 construction, and control of human biological systems at the molecular level, using  
20 engineered nanodevices and nanostructures. A consortium of Winston-Salem State  
21 University (Lead), Forsyth Technical Community College, and Wake Forest University  
22 will be responsible for the management of NCNanoMed. These entities will be advised  
23 by a consortium of existing therapeutics and medical device companies existent within  
24 North Carolina as well as other universities and colleges in North Carolina with nano  
25 expertise. Funds appropriated in this section shall be allocated for operations of the  
26 North Carolina Institute of NanoMedicine and shall be allocated in the following  
27 amounts for the following purposes:

- 1 (1) The Institute will build sets of tests, aimed at regulatory need, that are  
2 necessary for companies in the nanotherapeutic and regenerative  
3 medicine industry. To fully utilize existing biotechnology assets within  
4 North Carolina, the sum of six million dollars (\$6,000,000) from funds  
5 appropriated in this section will be allocated for the development of  
6 industrial-academic partnerships to establish these basic testing  
7 platforms and regulatory initiatives with the cooperation or guidance  
8 of the Food and Drug Administration. The partnerships will result in  
9 the rapid development of therapeutic products produced by nano- and  
10 emerging-tissue engineering and will support industrial growth in this  
11 sector by providing a competitive advantage in North Carolina.
- 12 (2) One million five hundred thousand dollars (\$1,500,000) for targeted  
13 recruiting of the top 30 performers in start-up biotech industries across  
14 the country, with the goal of demonstrating capabilities of  
15 NCNanoMed with its academic partners and form the basis of growth  
16 of new companies migrating to or new companies developing in this  
17 State. These companies will be approached as partnering opportunities  
18 for NCNanoMed. Of the funds allocated under this subdivision, the  
19 sum of five hundred thousand dollars (\$500,000) shall be used for  
20 management activities of the Central Management Core of  
21 NCNanoMed.
- 22 (3) One million dollars (\$1,000,000) to Forsyth Technical Community  
23 College, in partnership with NCNanoMed, for educational training and  
24 workforce development as it pertains to nanomedicine industrial need.  
25 This will again set North Carolina apart from competing economic  
26 regions as the only such region with a developed workforce in  
27 nanomedicine.
- 28 (4) Six million five hundred thousand dollars (\$6,500,000) for central  
29 facility development, five million dollars (\$5,000,000) of which will  
30 be used for Core laboratory equipment to establish specific centralized  
31 capabilities in therapeutic characterization not currently existing in this  
32 State and one million five hundred thousand dollars (\$1,500,000) of  
33 which will be used to provide incubator enhancement to include clean  
34 room space, product development space, and enhancement of  
35 laboratory floor space for use for newly recruited companies.

36 **SECTION 2.** This act becomes effective July 1, 2007.